Biotechnology
Biopharmaceutical
Pharmaceutical

Intercept Pharmaceuticals

7,114

$47.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.57 (+1.23%) Today
-$0.09 (-0.19%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ICPT and other stocks, options, ETFs, and crypto commission-free!

About ICPT

Intercept Pharmaceuticals, Inc. Common Stock, also called Intercept Pharmaceuticals, is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Read More Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

CEO
Mark E. Pruzanski
Employees
583
Headquarters
New York, New York
Founded
2002
Market Cap
1.55B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.12M
High Today
$47.23
Low Today
$45.08
Open Price
$47.21
Volume
1.13M
52 Week High
$125.00
52 Week Low
$44.50

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Research And Development
Technology

ICPT News

ReutersJun 29

BRIEF-Intercept Receives Complete Response Letter From FDA For Obeticholic Acid For The Treatment Of Fibrosis Due To Nash

June 29 (Reuters) - Intercept Pharmaceuticals Inc: * INTERCEPT RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR OBETICHOLIC ACID FOR THE TREATMENT OF FIBROSIS DU
0
MarketWatchJun 29

Intercept Pharmaceuticals receives FDA Complete Response Letter for treatment for fibrosis due to NASH

Intercept Pharmaceuticals Inc. shares ICPT, -2.65% tumbled more than 30% in premarket trade Monday, after the company said it has received a U.S. Food and Drug
0

ICPT Earnings

-$3.03
-$2.02
-$1.01
$0.00
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
— per share
Actual
Expected Aug 6, Pre-Market

You May Also Like

HIPS
FRI
FNDC
SRT
BJ
HMSY
ESGU
SPCE
FLQL
JSML
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy ICPT

Market Price$47.00
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell ICPT stock and options commission-free.
LearnBlogCareersHelpLog InSign Up